300404.SZ
博济医药
SZSE · M 科研服务 · CN
CNY 14.15
−1.94%Year over year
Reported trailing growth
- Revenue
- +33.1%
- EBITDA
- —
- EBIT
- +701.0%
- EPS
- +165.5%
- Free cash flow
- +55.0%
- Operating cash flow
- +30.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +27.0%
- EBITDA
- +16.1%
- EBIT
- +17.0%
- Net income
- +3.3%
- EPS
- +1.8%
- Free cash flow
- +2755.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026